Quantcast

Latest Roche Group Stories

2014-08-25 12:27:19

Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications PLEASANTON, Calif., Aug. 25, 2014 /PRNewswire/ -- Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody(1). This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 (MPDL3280A) immunotherapy development program and included in research of...

2014-08-25 12:26:15

Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications PLEASANTON, Calif., Aug. 25, 2014 /PRNewswire/ -- Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody(1). This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 (MPDL3280A) immunotherapy development program. The SP142 antibody is a...

2014-08-24 12:20:28

-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune's...

2014-08-07 16:27:47

-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models- SOUTH PLAINFIELD, N.J., Aug. 7, 2014 /PRNewswire/ -- Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy (SMA). Scientists from Roche Pharma Research and Early Development...

2014-07-29 12:35:02

Company's two-booth approach allows customers to see how Roche is partnering with them today and tomorrow CHICAGO, July 29, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling two booths (#1209 and #2009) focused on the unique ways Roche is partnering with customers to redefine the value of the laboratory. "Our customers tell us every day that they're looking for a...

2014-06-10 16:26:58

LAVAL, QC, June 10, 2014 /CNW Telbec/ - Roche announced that Health Canada approved the cobas® 4800 HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. Roche has also launched the fully automated CINtec® PLUS test to improve the detection and early intervention of pre-cancerous cervical disease. The Health Canada approved CINtec® PLUS cytology test helps identify women with high-grade pre-cancerous cervical...

2014-05-20 16:27:01

Formation of strategic alliance designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized predictive treatment INDIANAPOLIS, May 20, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. Established in 2002, Roche's MCOE program is...

2014-04-29 12:31:02

CHICAGO, April 29, 2014 /PRNewswire/ -- Roche Diagnostics has selected HY Connect, an independent, full-service agency, as a marketing and communications partner. Headquartered in Indianapolis, Indiana, Roche Diagnostics is the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche Diagnostics is also part of one of the world's leading research-oriented healthcare organizations - the Roche Group. HY Connect gained the...

2014-04-24 16:29:10

Expanded indication makes cobas® HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older PLEASANTON, Calif., April 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY)announced today that the U.S. Food and Drug Administration (FDA) approved the cobas(®) HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12...

2014-03-27 12:30:04

TUCSON, Ariz., March 27, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group has made an educational grant to support the World Health Organization (WHO) Clinical Advisory Meeting being held March 31 through April 1, 2014 in Chicago. The meeting's purpose is to update the existing WHO monograph on Tumours of the Haematopoietic and Lymphoid Tissues published in 2008. The meeting will be attended by up to 100 global experts in the field of...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related